RPG Life Sciences · NSE: RPGLIFE · BSE: 532983
Q4 FY22 results · Jan–Mar 2022
RPG Life Sciences reported revenue from operations of ₹103.80 crore (up 11.9% from Q4 FY21) and net profit of ₹7.52 crore (up 8.7% from Q4 FY21) for Q4 FY22 (Jan–Mar 2022), on a standalone basis.
| Item | Q4 FY22 | Q4 FY21 | YoY | Q3 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 103.80 | 92.76 | +11.9% | 115.58 | −10.2% |
| Other income | 1.26 | 0.30 | +320.0% | 0.61 | +106.6% |
| Total income | 105.06 | 93.06 | +12.9% | 116.19 | −9.6% |
| Profit before tax | 10.93 | 8.95 | +22.1% | 20.62 | −47.0% |
| Net profit for the period | 7.52 | 6.92 | +8.7% | 14.63 | −48.6% |
| EPS, basic (₹) | 4.55 | 4.18 | +8.9% | 8.85 | −48.6% |
| Net margin (%) | 7.2 | 7.5 | 12.7 |
Standalone
- Filed with BSE
- 10 May 2022, 16:18 IST
- Board meeting
- 29 Apr 2022
- Period
- 01 Jan 2022 to 31 Mar 2022
- Review status
- Audited
- Source
- XBRL filing on BSE